Pharmaceutical companies out-license, co-partner, and prioritize elements of their clinical pipelines to control costs and share risks. In light of this trend towards pharma outsourcing, specialized knowledge, resources and infrastructure, all of which are often needed globally, are efficiently delivered by a third party on an as-needed basis. Nowadays, resource management is thus more and more characterized by outsourcing which is becoming commonplace throughout the world and in all types of pharmaceutical and biotech companies. It permits access to specialized service providers when a certain technology or service is required for adapting operations to the development strategy on-demand and for reducing costs.
Innovation is becoming increasingly expensive as a result of rising research costs and the pressure to accelerate time to market for innovative products. Fewer blockbuster drugs are being developed. Drug development attrition rates have not yet been optimized in order to avoid late-stage failures with new product candidates. In global development in particular, the interest in bridging marketing interests with clinical development and regulatory strategy is challenging. Healthcare systems are attempting to curtail the costs of healthcare, in particular with regard to pharmaceuticals. All these camiseta selección factors increase the costs of development programmes and they are thus a major challenge for the pharmaceutical industry. To address all these challenges successfully, companies involve external expertise and resources to complement their own capabilities and speed up the development processes.
Nowadays, resource management is thus more and more characterized by outsourcing which is
没有评论:
发表评论